Abstract
Modafinil is a candidate compound for the treatment of cocaine addiction that binds to the dopamine transporter (DAT) in healthy humans, as observed by positron emission tomography (PET). This mechanism, analogous to that of cocaine, might mediate a putative therapeutic effect of modafinil on cocaine dependence, though the binding of modafinil to DAT has never been assessed in cocaine-dependent patients. We aimed at quantifying the DAT availability during a controlled treatment by modafinil, and its clinical and psychometric correlates in cocaine-dependent patients at the onset of abstinence initiation. Twenty-nine cocaine-dependent male patients were enrolled in a 3-month trial for cocaine abstinence. Modafinil was used in a randomized double-blind placebo-controlled design and was administered as follows: 400 mg/day for 26 days, then 300 mg/day for 30 days, and 200 mg/day for 31 days. Participants were examined twice during a 17-day hospitalization for their DAT availability using PET and [11C]-PE2I and for assessments of craving, depressive symptoms, working memory, and decision-making. Cocaine abstinence was further assessed during a 10-week outpatient follow-up period. Baseline [11C]-PE2I-binding potential covaried with risk taking and craving index in striatal and extrastriatal regions. A 65.6% decrease of binding potential was detected in patients receiving modafinil for 2 weeks, whereas placebo induced no significant change. During hospitalization, an equivalent improvement in clinical outcomes was observed in both treatment groups, and during the outpatient follow-up there were more therapeutic failures in the modafinil-treated group. Therefore, these results do not support the usefulness of modafinil to treat cocaine addiction.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Andersen ML, Kessler E, Murnane KS, McClung JC, Tufik S, Howell LL (2010). Dopamine transporter-related effects of modafinil in rhesus monkeys. Psychopharmacology 210: 439–448.
Anderson AL, Reid MS, Li SH, Holmes T, Shemanski L, Slee A et al (2009). Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend 104 (1-2): 133–139.
Balconi M, Finocchiaro R, Canavesio Y (2014). Reward-system effect (BAS rating), left hemispheric "unbalance" (alpha band oscillations) and decisional impairments in drug addiction. Addict Behav 39: 1026–1032.
Bechara A, Damasio AR, Damasio H, Anderson SW (1994). Insensitivity to future consequences following damage to human prefrontal cortex. Cognition 50 (1-3): 7–15.
Bechara A, Damasio H (2002). Decision-making and addiction (part I): impaired activation of somatic states in substance dependent individuals when pondering decisions with negative future consequences. Neuropsychologia 40: 1675–1689.
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961). An inventory for measuring depression. Arch Gen Psychiatry 4: 561–571.
Brett M, Anton J, Valabregue R, Poline J-B (2002). Region of interest analysis using an SPM toolbox. The 8th International Conference on Functional Mapping of the Human Brain; Sendai, Japan. June 2–6, 2002.
Carlson S, Martinkauppi S, Rama P, Salli E, Korvenoja A, Aronen HJ (1998). Distribution of cortical activation during visuospatial n-back tasks as revealed by functional magnetic resonance imaging. Cereb Cortex 8: 743–752.
Cisler JM, Elton A, Kennedy AP, Young J, Smitherman S, Andrew James G et al (2013). Altered functional connectivity of the insular cortex across prefrontal networks in cocaine addiction. Psychiatry Res 213: 39–46.
Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP (2005). A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 30: 205–211.
Dackis CA, Kampman KM, Lynch KG, Plebani JG, Pettinati HM, Sparkman T et al (2012). A double-blind, placebo-controlled trial of modafinil for cocaine dependence. J Subst Abuse Treat 43: 303–312.
Ernst M, Paulus MP (2005). Neurobiology of decision making: a selective review from a neurocognitive and clinical perspective. Biol Psychiatry 58: 597–604.
FDA (2007). Food and Drug Administration. Patient information leaflet for PROVIGIL® (modafinil) Tablet [C-IV].
Feltenstein MW, See RE (2008). The neurocircuitry of addiction: an overview. Br J Pharmacology 154: 261–274.
Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert FA, Fuxe K (1998). The effects of modafinil on striatal, pallidal and nigral GABA and glutamate release in the conscious rat: evidence for a preferential inhibition of striato-pallidal GABA transmission. Neurosci Lett 253: 135–138.
Grant S, Contoreggi C, London ED (2000). Drug abusers show impaired performance in a laboratory test of decision making. Neuropsychologia 38: 1180–1187.
Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ (1997). Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 6: 279–287.
Hart CL, Haney M, Vosburg SK, Rubin E, Foltin RW (2008). Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 33: 761–768.
Hirvonen J, Johansson J, Teras M, Oikonen V, Lumme V, Virsu P et al (2008). Measurement of striatal and extrastriatal dopamine transporter binding with high-resolution PET and [11C]PE2I: quantitative modeling and test-retest reproducibility. J Cereb Blood Flow Metab 28: 1059–1069.
Kampman KM, Lynch KG, Pettinati HM, Spratt K, Wierzbicki MR, Dackis C et al (2015). A double blind, placebo controlled trial of modafinil for the treatment of cocaine dependence without co-morbid alcohol dependence. Drug Alcohol Depend 155: 105–110.
Karila L, Reynaud M, Aubin HJ, Rolland B, Guardia D, Cottencin O et al (2011a). Pharmacological treatments for cocaine dependence: is there something new? Curr Pharm Des 17: 1359–1368.
Karila L, Seringe E, Benyamina A, Reynaud M (2011b). The reliability and validity of the French version of the Cocaine Craving Questionnaire-Brief. Curr Pharm Des 17: 1369–1375.
Kim D (2012). Practical use and risk of modafinil, a novel waking drug. Environ Health Toxicol 27: e2012007.
Kim W, Tateno A, Arakawa R, Sakayori T, Ikeda Y, Suzuki H et al (2014). In vivo activity of modafinil on dopamine transporter measured with positron emission tomography and [(1)(8)F]FE-PE2I. Int J Neuropsychopharmacol 17: 697–703.
Koob GF, Le Moal M (2001). Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24: 97–129.
Lammertsma AA, Hume SP (1996). Simplified reference tissue model for PET receptor studies. Neuroimage 4 (3 Pt 1): 153–158.
Li CS, Luo X, Sinha R, Rounsaville BJ, Carroll KM, Malison RT et al (2010). Increased error-related thalamic activity during early compared to late cocaine abstinence. Drug Alcohol Depend 109 (1-3): 181–189.
Madras BK, Xie Z, Lin Z, Jassen A, Panas H, Lynch L et al (2006). Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther 319: 561–569.
Marcusson J, Eriksson K (1988). [3H]GBR-12935 binding to dopamine uptake sites in the human brain. Brain Res 457: 122–129.
Mariani JJ, Levin FR (2012). Psychostimulant treatment of cocaine dependence. Psychiatr Clin North Am 35: 425–439.
Mereu M, Bonci A, Newman AH, Tanda G (2013). The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders. Psychopharmacology 229: 415–434.
Meyer JH, Gunn RN, Myers R, Grasby PM (1999). Assessment of spatial normalization of PET ligand images using ligand-specific templates. Neuroimage 9: 545–553.
Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382–389.
Naqvi NH, Bechara A (2009). The hidden island of addiction: the insula. Trends Neurosci 32: 56–67.
Narendran R, Martinez D (2008). Cocaine abuse and sensitization of striatal dopamine transmission: a critical review of the preclinical and clinical imaging literature. Synapse 62: 851–869.
Norbury A, Manohar S, Rogers RD, Husain M (2013). Dopamine modulates risk-taking as a function of baseline sensation-seeking trait. J Neurosci 33: 12982–12986.
O'Doherty JP (2011). Contributions of the ventromedial prefrontal cortex to goal-directed action selection. Ann NY Acad Sci 1239: 118–129.
Seki C, Ito H, Ichimiya T, Arakawa R, Ikoma Y, Shidahara M et al (2010). Quantitative analysis of dopamine transporters in human brain using [11C]PE2I and positron emission tomography: evaluation of reference tissue models. Ann Nuclear Med 24: 249–260.
Sekine Y, Minabe Y, Ouchi Y, Takei N, Iyo M, Nakamura K et al (2003). Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. Am J Psychiatry 160: 1699–1701.
Taber KH, Black DN, Porrino LJ, Hurley RA (2012). Neuroanatomy of dopamine: reward and addiction. J Neuropsychiatry Clin Neurosci 24: 1–4.
Tupala E, Halonen P, Tiihonen J (2006). Visualization of the cortical dopamine transporter in type 1 and 2 alcoholics with human whole hemisphere autoradiography. Eur Neuropsychopharmacol 16: 552–560.
Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F et al (2009). Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 301: 1148–1154.
Volkow ND, Fowler JS, Wang GJ (2004). The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies. Neuropharmacology 47 (Suppl 1): 3–13.
Volkow ND, Wang GJ, Telang F, Fowler JS, Logan J, Childress AR et al (2006). Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. J Neurosci 26: 6583–6588.
Wong DF, Kuwabara H, Schretlen DJ, Bonson KR, Zhou Y, Nandi A et al (2006). Increased occupancy of dopamine receptors in human striatum during cue-elicited cocaine craving. Neuropsychopharmacology 31: 2716–2727.
Acknowledgements
The research was monitored by the Unité de Recherche Clinique des Hôpitaux Universitaires Paris Sud (Professor Laurent Becquemont). We thank Ms Christine Baron, Mr Claude Comtat, Mr Frédéric Dollé, Ms Rose-Marie Dubuisson, Mr Philippe Gervais, and Mr Renaud Maroy from the Service Hospitalier Frédéric Joliot for their efficient technical support.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Neuropsychopharmacology website
Supplementary information
Rights and permissions
About this article
Cite this article
Karila, L., Leroy, C., Dubol, M. et al. Dopamine Transporter Correlates and Occupancy by Modafinil in Cocaine-Dependent Patients: A Controlled Study With High-Resolution PET and [11C]-PE2I. Neuropsychopharmacol 41, 2294–2302 (2016). https://doi.org/10.1038/npp.2016.28
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/npp.2016.28
This article is cited by
-
Imaging Procedure and Clinical Studies of [18F]FP-CIT PET
Nuclear Medicine and Molecular Imaging (2024)
-
A systematic review of the potential effects of medications and drugs of abuse on dopamine transporter imaging using [123I]I-FP-CIT SPECT in routine practice
European Journal of Nuclear Medicine and Molecular Imaging (2023)
-
Neuroimaging of Dopamine Transporter Density in the Striatum of Disordered Gamblers
Journal of Gambling Studies (2022)
-
Fully automated radiosynthesis of [18F]LBT999 on TRACERlab FXFN and AllinOne modules, a PET radiopharmaceutical for imaging the dopamine transporter in human brain
EJNMMI Radiopharmacy and Chemistry (2020)
-
Improving translation of animal models of addiction and relapse by reverse translation
Nature Reviews Neuroscience (2020)
